Tag Archives: pricing

Who's Watching the Drug Watchdogs?

It is nowadays fashionable to question everyone in authority, and there is no shortage of self-appointed watchdogs who aim to make sure that things that happen are happening as they should. The drug industry and drug regulatory authorities have been among the most conspicuous targets of this intense monitoring, on everything from questionable payments to […]
Posted in Europe, Global, Guest Blog, Op-Ed, Regulatory | Also tagged , , , , | 1 Comment

UK: Is Value Based Assessment the New Value Based Pricing?

NICE and Value Based Assessment: An Update By Leela Barham VBA is the new VBP The initial proposals for Value Based Pricing (VBP) have evolved into something very different.  Now there is focus on Value Based Assessment (VBA), which is really focusing on adding just two factors to the usual methods of assessing new medicines: […]
Posted in Europe, Global, Guest Blog, pricing | Also tagged , , , , , | Leave a comment

England: Is the Cancer Drugs Fund Running Out of Money?

By Leela Barham. The headlines have moved on for the English Cancer Drugs Fund (CDF). Replacing the positive press releases such as “thousands of patients to benefit” in 2013 are headlines shouting out that “thousands face being denied life-extending medication”.  In other words, a return to the same concerns that prompted the creation of the […]
Posted in Europe, Global, Guest Blog, pricing, Regulatory | Also tagged , , , | 1 Comment

Roche Jumps into Medicines Patent Pool with Pricing and Licensing Deal

Roche this week has announced a partnership with the UN-backed Medicines Patent Pool (MPP) to provide its drug valganciclovir, better known in the developed world as Valcyte, in 138 countries for a reduced price. In addition to making the drug available in these markets for up to 90% cheaper than current price, Roche has decided […]
Posted in Corporate Responsibility, Deals, Emerging Markets, Global, IP, Market Access, pricing | Also tagged , , , , , , , , , , , , , , , , , , , | Leave a comment

UK: NICE's Looming Value-Based Pricing Challenges

NICE role in VBP The National Institute for Health and Care Excellence (NICE) will have a vital role in the post 2014 value based pricing (VBP) world.  The Department of Health (DH) who still act as the sponsor organization for the agency, has set out in more detail just what value assessment by NICE will […]
Posted in Guest Blog, Op-Ed, pricing | Also tagged , , , , | Leave a comment
  • Categories

  • Meta